Peptic ulcer bleeding is an internal medical emergency. Endoscopic hemostasis has been shown to improve the survival rate of patients with peptic ulcer bleeding. Although the established hemostatic modalities, including injection, thermal therapy, and mechanical therapy, are effective in controlling peptic ulcer bleeding, hemostasis can be difficult to achieve in some cases. As a result, recent, new endoscopic hemostatic modalities, including over-the-scope clips, topical hemostatic sprays, and endoscopic ultrasonography-guided angiotherapy, have been developed. Clin Endosc 2016;49:417-420
INTRODUCTION
Upper gastrointestinal bleeding (UGIB) is a potentially lethal internal medical emergency. Its incidence rate is 40 to 150 cases per 100,000 populations. 1, 2 Approximately 80% to 90% of UGIB cases are associated with nonvariceal bleeding, predominantly peptic ulcer bleeding. 3, 4 Owing to the development of endoscopic management and increased use of proton pump inhibitors for the treatment of these patients, the incidence rate of UGIB has been decreasing; however, the incidence rate of peptic ulcer bleeding caused by aspirin and nonsteroidal anti-inflammatory drugs has been increasing. 5, 6 Despite the decrease in the incidence rate of UGIB and the advancement of therapeutic techniques, the mortality rate of patients with UGIB has remained unchanged at 10% to 14% for the past 30 years. 5 This fact has been attributed to the increase in the aging population with other comorbid conditions and to patients not receiving endoscopic management in time, which could have increased their survival. The aim of this lecture is to provide information on the updated endoscopic treatment of bleeding peptic ulcer.
GOALS OF ENDOSCOPIC MANAGEMENT
The short-term goal for treating patients with UGIB is the prevention of rebleeding, and the long-term goal is to lower the associated mortality rate. In a meta-analysis, endoscopic management was a more effective treatment than pharmacological managements or placebo for lowering the rebleeding and mortality rates in patients with UGIB. 7 Prognostic factors that are associated with higher mortality of patients with UGIB include old age, comorbid conditions, history of shock at the time of hospital visit, consistent bleeding, and rebleeding. 8 Although endoscopic management cannot alleviate the effects of the aforementioned prognostic factors such as old age, comorbid conditions, and shock at the time of hospital visit, it may lower the mortality of patients with UGIB by preventing consistent bleeding and rebleeding.
ENDOSCOPIC MANAGEMENT
Patients with acute UGIB are recommended to undergo early endoscopic management within 24 hours of their hospital visit. 9 Early endoscopic management has been reported to decrease the length of hospitalization, in comparison with delayed endoscopy, in high-and low-risk groups. 10 The efficacy of endoscopic management in the treatment of patients with ulcers with adherent clots is controversial. According to a study, 26% to 43% of adherent clots could be removed through vigorous irrigation and approximately 70% of visible vessels were observed on the ulcer base after clot removal. 13 Therefore, endoscopic management is efficacious in only 50% to 60% of patients with FIIb. Moreover, the reported risk of rebleeding range from 0%-8% to 25%-35% in patients with clots that remain adherent after washing without endoscopic therapy, and whether endoscopic management is efficacious in patients with FIIb remains unclear. 13 Therefore, endoscopic management must be performed only after clots have been removed from the ulcer base, when the ulcer base is actively bleeding, or when vessels are visible.
ENDOSCOPIC HEMOSTASIS
Endoscopic hemostasis can be divided into monotherapy and combined therapy. Monotherapy includes injection, thermal, mechanical modalities, and topical therapy.
Injection therapy
Injection therapy stops hemorrhage by inducing local tamponade resulting from a volume effect. Epinephrine, distilled water, cyanoacrylate, ethanolamine, thrombin, sodium tetradecyl sulfate, ethanol, and fibrin glue are used as injection therapy. Epinephrine injection (1:10,000 or 1:20,000 with normal saline injected in 0.5 to 2 mL aliquots in and around the ulcer base) has shown hemostatic effects not only through induction of local tamponade but also through vasoconstriction and platelet aggregation.
14 Although epinephrine injection is more effective than medical treatment for hemostasis, its therapeutic efficacy has been suboptimal compared with other endoscopic hemostatic modalities. Therefore, epinephrine injection alone is no longer recommended and should be used in combination with another method. Combining epinephrine injection with another hemostasis modality has shown decreased rates of rebleeding, surgery, and mortality compared with epinephrine injection alone. 15 Sclerosing agents such as absolute ethanol, ethanolamine, and polidocanol induce hemostasis through direct injury of blood vessels and thrombosis. The volume of sclerosing agents must be controlled before injection to avoid possible necrosis and perforation. Another class of injectable agents is tissue adhesives, which includes thrombin, fibrin, and cyanoacrylate glues that plug bleeding sites. No single solution for endoscopic injection is superior to another for inducing hemostasis.
Thermal therapy
In thermal therapy, visible vessels are directly destroyed. Thermal therapy includes contact and noncontact modalities. In contact thermal therapy, heater probe, bipolar electrocautery probes, and hemostatic forceps are used; while in noncontact thermal therapy, argon plasma coagulation (APC) is used. In contact thermal therapy, a heater probe generates heat directly, and bipolar electrocautery probes induce hemostasis via indirect generation of heat by passage of an electrical current through the tissue. In contact thermal therapy, the tip of the instrument is placed on a visible vessel, which is then coagulated with heat or electrical current. The standard setting for hemostasis of peptic ulcer bleeding is 15 to 20 W for 8 to 10 seconds. 12 Hemostatic forceps are used to stop hemorrhage in the same way that biopsy forceps are used. We compared the hemostatic effects of hemostatic forceps and APC in a randomized, prospective manner. 16 The rebleeding rate was 6.6% within 7 days and 9.9% within 30 days in the hemostatic forceps group, and 4.0% within 7 days and 6.7% within 30 days in the APC group. No significant difference in bleeding rate was found between the two groups. This study concluded that hemostatic forceps are safer than and as effective as APC in the treatment of peptic ulcer bleeding. 16 Noncontact thermal devices include APC tools. APC uses high-frequency, monopolar alternating current conducted to the target tissue through a stream of ionized gas, resulting in coagulation of superficial tissue. 17 Hemostasis is considered successful once bleeding is stopped and black carbide crusts form. An advantage of this technique is that it allows for eas-ier access to lesions that are normally difficult to approach. In addition, as the tissue surface loses its electrical conductivity, the argon plasma stream shifts to adjacent nondesiccated tissue, which again limits the depth of tissue injury. The electrocoagulative effect may carry a lower risk of intestinal perforation. Therefore, APC produces effective hemostatic results in superficial vascular lesions such as angiodysplasia and gastric antral vascular ectasia. No single application of endoscopic thermal coagulation is superior to another.
Mechanical therapy
In endoscopic mechanical therapies, clips (through-thescope clips and over-the-scope clips [OTSCs]), band ligation devices, and detachable loop-ligating devices may be used. A clip induces hemostasis by mechanical compression that passes through the ulcer base. Once a clip is fixed onto the base, it sloughs off within days to weeks. 18 The through-the-scope clip is the most commonly used type. Many kinds of hemoclip devices have been developed, with variations in opening diameter, ease of rotation, and reopening. The major limitation of hemoclips is that they may be difficult to use in hard-toaccess areas such as the lesser curvature of the gastric body, posterior duodenum, or cardia. Moreover, if the ulcer base has hardened as a result of fibrosis, a clip may not be able to pierce through the ulcer base and touch vessels instead, which leads to bleeding. In addition, misplaced clips may become a hindrance during the next endoscopic therapy. Despite these shortcomings, clips are more effective than injection monotherapy.
11,13
Endoscopic band ligation is typically used to achieve hemostasis in patients with esophageal variceal bleeding, Dieulafoy' s lesion, Mallory-Weiss syndrome, and bleeding ulcers of small size. 19 An OTSC device consists of an applicator cap, nitinol clip, and handwheel. 20 The applicator cap, with the mounted nitinol clip, is affixed to the tip of the endoscope in a manner similar to that in a variceal band ligation device. After placing the endoscope tip near the lesion, the tissue is suck into the applicator cap and the clip is ejected by stretching the wire with the handwheel to stop hemorrhage. Clips come in two different shapes of teeth, rounded and pointed. According to a recent study, the OTSC attained 100% hemostasis, and the rebleeding prevention rate was 80% in patients with UGIB. 21 The disadvantages of the OTSC are that it requires the scope to be withdrawn to load the device, the OTSC cap may make traversing the cricopharyngeus or luminal stenoses difficult, accessing the lesions in the posterior-inferior duodenal wall or proximal lesser curvature of the stomach is challenging, and its cost is high. To our knowledge, no prospective studies have been conducted to compare the hemostatic effects of OTSCs and through-the-scope clips, and the role of OTSCs in the treatment of patients with UGIB is still unclear. Today, OTSC is used in rescue hemostatic therapy when conventional endoscopic treatment modalities fail and in closure of iatrogenic full-thickness perforations of the gastrointestinal tract.
Topical therapy
Topical hemostatic spray has shown promising results in the treatment of patients with UGIB. However, these results cannot be completely trusted because of the small sample size and no studies have compared topical hemostatic spray with other hemostatic therapies. 22 The advantages of using a hemostatic spray include the following: (1) it is easy to use and simply sprayed; (2) the lesion does not have to be precisely targeted; and (3) it allows for easier access to sites that are normally hard to access. Three types of topical hemostatic sprays have been developed as follows: TC-325, (Hemospray; Cook Medical Inc., Winston-Salem, NC, USA), EndoClot (EndoClot Plus Inc., Santa Clara, CA, USA), and Ankaferd Blood Stopper (Ankaferd Health Products Ltd., Istanbul, Turkey). TC-325 is a proprietary, inorganic, absorbent powder that activates coagulation factors near the hemorrhage site and forms coagulum to produce hemostatic effects. Coagulum is naturally peeled off and removed within 3 days of application. In a recent study of 20 patients with UGIB, researchers investigated the safety and efficacy of hemospray. No side effects, death, or complications from bleeding were observed during the 30-day follow-up for acute bleeding at 95%. In a group of patients at high risk of rebleeding (FIa and Ib), hemostasis was also performed at 90% and the risk of rebleeding within 7 days was 22%. 23 EndoClot is a starch-derived compound that induces hemostasis by activating a coagulating process where water is absorbed into the hemorrhage site from serum, and platelets, erythrocytes, and coagulated proteins agglutinate together. Ankaferd Blood Stopper promotes the formation of a protein mesh, which becomes a foothold for hemaglutination without the influence of platelet coagulation factors. Topical agents are effective for inducing hemostasis of oozing-type lesions. The hemostatic effects of topical agents in active arterial bleeding have not been verified because hemostatic agents cannot effectively attach to the hemorrhage site but tend to get washed away by the continuous bleeding. Moreover, topical agents have been reported to be lacking in the case of FIIa. In a systematic review of the current limited data, hemospray is considered a bridge therapy because it is safe and effective, but has temporary effects. 22 A more-randomized prospective research is warranted to verify the effectiveness of hemostatic powders in the treatment of patients with peptic ulcer bleeding.
Endoscopic ultrasonography-guided angiotherapy
The effectiveness of endoscopic ultrasonography (EUS)-guided angiotherapy has been investigated by a number of small-scale studies. 24 EUS-guided angiotherapy was effective in patients with lesions that had not been effectively treated with typical endoscopic therapies. EUS-guided angiotherapy therapy involves identification of vessels around the hemorrhage site by using EUS before performing hemostasis. Recently, EUS-guided cyanoacrylate injection was reported to be a relatively safe method and to have prevented rebleeding in the long term in patients with duodenal ulcers.
CONCLUSIONS
Injection of sclerosants, thermal therapy, and mechanical therapy as monotherapy or in combination with epinephrine injection are currently the most recommended and effective methods of achieving hemostasis. Topical therapy and OTSCs have been developed to attain greater hemostatic effects more easily; however, more large-scale studies are needed to confirm their usefulness, efficacy, and safety.
